{
  "docId": "019dd923-5eff-723e-9be8-8ecf5ec778da",
  "docSlug": "2EobkBpnCoKZCisTIQTA",
  "documentTitle": "Here's the 13-slide pitch deck ReCode Therapeutics used to raise $120 million from OrbiMed and Pfizer to develop new mRNA medicines",
  "authorId": "Pitchdecks",
  "authorName": "ReCode Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.774,
  "pageNumber": 12,
  "pageCount": 13,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a circular diagram to represent the SORT LNP platform surrounding a genetic payload, paired with four key business highlights.",
  "elementsJson": [
    "action_title",
    "icon_grid",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5eff-723e-9be8-8ecf5ec778da/12",
  "deckHref": "/decks/019dd923-5eff-723e-9be8-8ecf5ec778da",
  "deckJsonHref": "/decks/019dd923-5eff-723e-9be8-8ecf5ec778da.json",
  "deckAnchorHref": "/decks/019dd923-5eff-723e-9be8-8ecf5ec778da#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.35,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "SORT LNPs PLATFORM surrounding GENETIC PAYLOAD",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "378de1d3-05b1-475c-8cfa-234ba583558e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.5,
        "x": 0.45,
        "y": 0.25
      },
      "kind": "list",
      "text": "Highly experienced leadership team; Lead indications in PCD and CF with genetically validated targets; Platform expansion beyond lung with diverse payloads and formulations; Cash runway through end of 2024; Opportunities for partnering and additional capital formation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "faafd770-3bf1-4367-ab23-bba9eee19934",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Leveraging SORT to power the delivery of genetic medicines",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73dbb5b5-be25-461f-b85d-57a9a76caad5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "e0d2401d-ff86-427e-b36f-9b6acd1a5464",
      "evidence": "list/bullet: Highly experienced leadership team; Lead indications in PCD and CF with genetically validated targets; Platform expansion beyond lung with diverse payloads and formulations; Cash runway through end of 2024;",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}